What Quest Diagnostics (DGX) Said on Its Q3 Earnings Call

Quest Diagnostics raises 2026 outlook after Q3 growth

Quest Diagnostics raises its 2026 revenue and earnings outlook after testing growth, while management outlines potential Medicare payment pressure for 2027.

What Quest Diagnostics (DGX) Said on Its Q3 Earnings Call

Quest Diagnostics (NYSE:DGX) reported third-quarter 2026 revenue growth of 10% and adjusted earnings-per-share growth of more than 15%, citing demand across its physician, hospital and consumer channels as well as productivity gains from automation and artificial intelligence. The company raised and

Quest Diagnostics (DGX) Q3 2026 Earnings Call Transcript

Revenue grew 10% as automation and AI boosted margins amid regulatory headwinds.

Quest Diagnostics outlines $12.065B-$12.105B 2026 revenue outlook while projecting consumer health growth to exceed 30% (NYSE:DGX)

Quest Diagnostics Q3 2026: raised guidance, Apple Health lab ordering, and PAMA risk.

Quest Diagnostics Lifts 2026 Revenue and Earnings Targets After Q3 Beat

Third-quarter revenue rose 10% year over year to $3.097 billion, while adjusted diluted earnings reached $3 per share.